Chapter 5 │ Page 195 93. A. Daniel-Wójcik, K. Misztal, I. Bechyne, J. Sroka, K. Miekus, Z. Madeja, J. CZYZ, Cell motility a ects the intensity of gap junctional coupling in prostate carcinoma and melanoma cell populations, Int. J. Oncol. 33 (2008) 309-315. 94. S. Sirnes, J. Bruun, M. Kolberg, A. Kjenseth, G. E. Lind, A. Svindland, A. Brech, A. Nesbakken, R. A Lothe, E. Leithe, E. Rivedal, Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome, Int. J. Cancer 131 (2012) 570-581. 95. T. Valenta, G. Hausmann, K. Basler, The many faces and functions of β-catenin, 31 (2012) 2714-2736. 96. T. Weinert, D. Lydall, Cell cycle checkpoints, genetic instability and cancer, Semin. Cancer Biol. 4 (1993) 129-140. 97. T. K. Nelson, P. L. Sorgen, J. M. Burt, Carboxy terminus and pore-forming domain properties specific to Cx37 are necessary for Cx37-mediated suppression of insulinoma cell proliferation, Am. J. Physiol. Cell Physiol. 305 (2013) C1246-C1256. 98. H. Jee, S-H. Lee, J-W. Park, B-R. Lee, K-T. Nam, D-Y. Kim, Connexin32 inhibits gastric carcinogenesis through cell cycle arrest and altered expression of p21(Cip1) and p27(Kip1), BMB Rep. 46 (2013) 25-30. 99. Y. Yang, N. Zhang, J. Zhu, X. T. Hong, H. Liu, Y. R. Ou, F. Su, R. Wang, Y. M. Li, Q. Wu, Downregulated connexin32 promotes EMT through the Wnt/β-catenin pathway by targeting Snail expression in hepatocellular carcinoma, Int. J. Oncol. 50 (2017) 19771988. 100. X-T. Fu, Z. Dai, K. Song, Z-J. Zhang, Z-J. Zhou, S-L. Zhou, Y-M. Zhao, Y-S. Xiao, Q-M. Sun, Z-B. Ding, J. Fan, Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway, Int. J. Oncol. 46 (2015) 587-596. 101. M. K. Stewart, J. F. Bechberger, I. Welch, C. C. Naus, D. W. Laird, Cx26 knockout predisposes the mammary gland to primary mammary tumors in a DMBA-induced mouse model of breast cancer, Oncotarget 6 (2015) 37185-37199. 102. M. Uhlen, C. Zhang, S. Lee, E. Sjostedt, L. Fagerberg, G. Bidkhori, R. Benfeitas, M. Arif, Z-T. Liu, F. Edfors, K. Sanli, K. von Feilitzen, P. Oksvold, E. Lundberg, S. Hober, P. Nilsson, J. Mattsson, J. M. Schwenk, H. Brunnstrom, B. Glimelius, T. Sjoblom, P-H. Edqvist, D. Djureinovic, P. Micke, C. Lindskog, A. Mardinoglu, F. Ponten, A pathology atlas of the human cancer transcriptome, Science 357 (2017) 660. 103. T. J. King and P. D. Lampe, The gap junction protein connexin 32 is a mouse lung tumor suppressor, J. Cancer Res. 64 (2004) 7191-7196. 104. Y. Yang, J-H. Yao, Q-Y. Du, Y-C. Zhou, T-J. Yao, Q. Wu, J. Liu, Y-R. Ou, Connexin 32 downregulation is critical for chemoresistance in oxaliplatin-resistant HCC cells associated with EMT, Cancer Manag. Res. 11 (2019) 5133-5146. 105. T. J. King, K. E Gurley, J. Prunty, J-L. Shin, C. J. Kemp, P. D. Lampe, Deficiency in the gap junction protein connexin32 alters p27Kip1 tumor suppression and MAPK activation in a tissue-specific manner, Oncogene 24 (2005) 1718-1726. 106. I. Igarashi, T. Makino, Y. Suzuki, K. Kai, M. Teranishi, W. Takasaki, K. Furuhama, Background lesions during a 24 -month observation period in connexin 32 - deficient mice, J. Vet. Med. Sci. 75 (2013) 207-210. 107. H. Luo, X. Wang, H. Ge, N. Zheng, F. Peng, Y. Fu, L. Tao, Q. Wang, Inhibition of ubiquitinspecific protease 14 promotes connexin 32 internalization and counteracts cisplatin cytotoxicity in human ovarian cancer cells, Oncol. Rep. 42 (2019) 1237-1247.
RkJQdWJsaXNoZXIy MTk4NDMw